Oncology Collaboration Memgen's MEM-288 oncolytic virus, developed in collaboration with Moffitt Cancer Center, is nearing completion of the NSCLC monotherapy trial, presenting a compelling opportunity for large oncology partners to co-develop or license a potent immunotherapy platform to expand into solid tumors.

Adjuvant Platform MemVax is a vaccine adjuvant designed to bolster immune responses across vaccine modalities, with 100,000 doses ready for clinical trials and an active FDA file, creating potential partnerships with vaccine developers to co-advance MemVax in infectious disease and cancer vaccines.

Regulatory Readiness The company holds an active FDA file and a pathway to initiate trials, offering a de-risked entry point for strategic partners and the potential to accelerate deal timelines and regulatory-aligned collaboration structures.

Novel Immunology The MEM40 transgene platform provides a differentiated mechanism within viral immunotherapies, enabling potential licensing or milestone-driven partnerships with larger biotech firms seeking novel modalities to augment their immuno-oncology portfolios.

Partnership Model With a small team and established academic collaborations, Memgen can leverage CRO/CMO partnerships to scale development and manufacturing efficiently, shortening deal cycles and enabling faster licensing or co-development opportunities.